ÀÓ»óÁú¹® (Clinical Question)
Q: ±¹¼ÒÀûÀ¸·Î ÀüÀÌµÈ À¯¹æ¾Ï ȯÀÚ¿¡°Ô adriamycin and docetaxel (AD)±º°ú ½Åº¸Á¶Ç×¾ÏÈÇпä¹ýÀ¸·Î adriamycin, cyclophosphamide followed by paclitaxel (AC-T) Ä¡·á ½Ã µÎ ±º°£ Â÷ÀÌ°¡ ÀÖ½À´Ï±î?
±Ù°Å±â¹Ý ´äº¯ (Evidence-based Answer)
A: AC-T ¿ä¹ýÀº AD ¿ä¹ý°ú ºñ±³ÇÏ¿© È¿´É¸é¿¡¼ À¯»çÇÏ¿´À¸¸ç, Á¾¾ç ¹ÝÀÀ¿¡¼´Â µÎ ±º°£ÀÇ ´Ù¾çÇÑ º¯¼ö¿¡¼ Â÷ÀÌ°¡ ¾ø¾ú½À´Ï´Ù. ±×·¯³ª AD ±ºÀÇ ´ëºÎºÐÀÇ ¿©¼ºµéÀº 3/4 µî±ÞÀÇ È£Áß±¸ °¨¼ÒÁõ (P <0.001)°ú È£Áß±¸ °¨¼Ò¼º ¹ß¿ (P <0.001)À¸·Î °íÅëÀ» ¹Þ¾ÒÀ½À» º¸°íÇÏ°í ÀÖÀ¸¹Ç·Î, AC-T´Â ½Åº¸Á¶ ÈÇпä¹ýÀ»¹Þ´Â À¯¹æ¾Ï ȯÀÚ¿¡¼ AD Ä¡·áº¸´Ù´Â Á¶±Ý ´õ °ßµð±â ½¬¿î Ä¡·á·Î º¸°íµÇ¾ú½À´Ï´Ù.
Ãâó (Source)
Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer, ´ëÇÑ¿Ü°úÇÐȸÁö, 2013³â 85±Ç 1È£ p.7 ~ p.14, https://doi.org/10.4174/jkss.2013.85.1.7